213
Views
4
CrossRef citations to date
0
Altmetric
Letter to the Editor

Intravitreal Administration of Ranibizumab and Bevacizumab for Choroidal Neovascularization Secondary to Ocular Toxocariasis: A Case Report

, MD & , MD, PhD
Pages 639-641 | Received 18 Mar 2016, Accepted 19 Sep 2016, Published online: 24 Oct 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ana Navarrete, Milka Matanis-Suidan, Itzhak Hemo, Hadas Mechoulam, Eyal Banin & Radgonde Amer. (2023) Enhanced S-Cone Syndrome Masquerading as TORCH in an Infant and a Toddler. Ocular Immunology and Inflammation 31:2, pages 455-461.
Read now

Articles from other publishers (3)

Youran Cai, Ye Yang & Xin Zhong. (2022) A Case Report of Intravitreal Dexamethasone Implant with Exudative Retinal Detachment for Ocular Toxocariasis Treatment. The Korean Journal of Parasitology 60:2, pages 133-137.
Crossref
Aniruddha Agarwal, Alessandro Invernizzi, Rohan Bir Singh, William Foulsham, Kanika Aggarwal, Sabia Handa, Rupesh Agrawal, Carlos Pavesio & Vishali Gupta. (2018) An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. Journal of Ophthalmic Inflammation and Infection 8:1.
Crossref
Pedro Ernesto Huapaya Herreros. (2017) Human Toxocariosis: Is it not a Public Health Problem Yet?. MOJ Biology and Medicine 2:4.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.